Cidara Therapeutics Announces Two Presentations on Innovative Drug-Fc Conjugate, CD388, at the 2024 OPTIONS XII for the Control of Influenza Conference
25 sept. 2024 08h00 HE
|
Cidara Therapeutics, Inc.
SAN DIEGO, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC)...
Cidara Therapeutics Announces First Subjects Dosed in Phase 2b NAVIGATE Trial Evaluating CD388 for the Prevention of Seasonal Influenza
23 sept. 2024 08h00 HE
|
Cidara Therapeutics, Inc.
SAN DIEGO, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC)...
Cidara Therapeutics Strengthens its Scientific Advisory Board with Infectious Disease Experts
19 sept. 2024 08h00 HE
|
Cidara Therapeutics, Inc.
SAN DIEGO, Sept. 19, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC)...
Cidara Therapeutics Restructures Workforce to Focus on Planned Clinical Development of CD388
12 sept. 2024 16h05 HE
|
Cidara Therapeutics, Inc.
SAN DIEGO, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC)...
Cidara to Present at the H.C. Wainwright 26th Annual Global Investment Conference
05 sept. 2024 08h00 HE
|
Cidara Therapeutics, Inc.
SAN DIEGO, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX) (the Company), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate...
Cidara Therapeutics Announces Appointment of Jim Beitel as Chief Business Officer
19 août 2024 17h12 HE
|
Cidara Therapeutics, Inc.
SAN DIEGO, Aug. 19, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC)...
Cidara Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results
13 août 2024 16h29 HE
|
Cidara Therapeutics, Inc.
SAN DIEGO, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX) (the Company), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate...
Cidara Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
03 juil. 2024 13h05 HE
|
Cidara Therapeutics, Inc.
SAN DIEGO, July 03, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC)...
Cidara Therapeutics to Present Preclinical Data on CD388 at ASM Microbe 2024 Conference
30 mai 2024 08h00 HE
|
Cidara Therapeutics, Inc.
SAN DIEGO, May 30, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC)...
Cidara Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
15 mai 2024 16h20 HE
|
Cidara Therapeutics, Inc.
SAN DIEGO, May 15, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX) (the Company), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate...